#Breaking: Pivotal Phase III results in previously treated KRAS G12C-mutated non-small cell lung cancer presented as an ESMO late-breaker and simultaneously published in the @NEJM. Learn more about our commitment to advancing innovation in #LungCancer: gene.com/media/press-re…
Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz

